Relmada Therapeutics Inc
Change company Symbol lookup
Select an option...
RLMD Relmada Therapeutics Inc
BAC Bank of America Corp
BSRR Sierra Bancorp
MSI Motorola Solutions Inc
ESI Element Solutions Inc
INVZW Innoviz Technologies Equity Warrant Exp 05 April 2026 *W EXP 04/05/2026
BEN Franklin Resources Inc
FLFG Federal Life Group Inc
GIIXU Gores Holdings VIII Inc
AEE Ameren Corp
Go

Health Care : Pharmaceuticals | Small Cap Growth
Company profile

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), which is an N-methyl-D-aspartate (NMDA) receptor antagonist. The Company’s lead product candidate, esmethadone, is a new chemical entity (NCE) developed as a rapidly acting, oral agent for the treatment of depression, central nervous system (CNS) diseases and other potential indications. The Company’s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission and is in development for both the adjunctive or monotherapy treatment of major depressive disorder (MDD).

Price
Delayed
$4.24
Day's Change
-0.215 (-4.83%)
Bid
--
Ask
--
B/A Size
--
Day's High
4.44
Day's Low
4.21
Volume
(Light)

Today's volume of 222,221 shares is on pace to be much lighter than RLMD's 10-day average volume of 713,075 shares.

222,221
  • Prev Close
    4.45
  • Today's Open
    4.41
  • Day's Range
    4.21-4.44
  • Avg Vol (10-day)
    713.1K
  • Last (time)
    12:20p ET 12/06/22
  • Last (size)
    100
  • 52-Wk Range
    4.21 - 38.68
    LowHigh
  • (09/30/22 - 12/06/22)
    0.59%
  • 172.3%
  • Market Cap
    127.5M
  • Shares Outstanding
    30.1M
  • -5.85
  • --
  • No dividend
  • Ex-dividend Date
    No dividend
  • Dividend Pay Date
    No dividend
  • 0.0
  • 96.63
  • (% of float 11/15/22)
    10.15

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.